Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Surrogate end points and FDA approval: a tale of 2 lipid-altering drugs.

× No keyword cloud information.

6 in total

1. Prostate-specific antigen: a misused and maligned prostate cancer biomarker.

Authors: Ian M Thompson; Catherine M Tangen; Alan R Kristal
Journal: J Natl Cancer Inst Date: 2008-10-28 Impact factor: 13.506

2. Assessment of new technologies: surrogate endpoints versus outcomes, and the cost of health care.

Authors: George A Beller
Journal: J Nucl Cardiol Date: 2008 May-Jun Impact factor: 5.952

Review 3. Regulatory landscapes for biomarkers and diagnostic tests: Qualification, approval, and role in clinical practice.

Authors: William B Mattes; Federico Goodsaid
Journal: Exp Biol Med (Maywood) Date: 2017-11-07

4. The challenge of designing a treatment trial for warfarin-associated intracerebral hemorrhage.

Authors: Matthew L Flaherty; Opeolu Adeoye; Padmini Sekar; Mary Haverbusch; Charles J Moomaw; Haiyang Tao; Joseph P Broderick; Daniel Woo
Journal: Stroke Date: 2009-03-12 Impact factor: 7.914

5. The role of surrogate endpoints in the evaluation of efficacy and safety of therapeutic interventions in diabetes mellitus.

Authors: Aleksandra Wieczorek; Przemyslaw Rys; Iwona Skrzekowska-Baran; Maciej Malecki
Journal: Rev Diabet Stud Date: 2008-11-10

Review 6. Emerging therapeutic strategies to enhance HDL function.

Authors: Santiago Redondo; José Martínez-González; Concha Urraca; Teresa Tejerina
Journal: Lipids Health Dis Date: 2011-10-10 Impact factor: 3.876

6 in total